BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38326737)

  • 1. Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy.
    Kim MW; Lee H; Lee S; Moon S; Kim Y; Kim JY; Kim SI; Kim JY
    BMC Cancer; 2024 Feb; 24(1):185. PubMed ID: 38326737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Jung HH; Kim JY; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM
    Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
    Derouane F; Desgres M; Moroni C; Ambroise J; Berlière M; Van Bockstal MR; Galant C; van Marcke C; Vara-Messler M; Hutten SJ; Jonkers J; Mourao L; Scheele CLGJ; Duhoux FP; Corbet C
    Breast Cancer Res; 2024 Feb; 26(1):29. PubMed ID: 38374113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Transcriptomic Changes After Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Orozco JIJ; Grumley JG; Matsuba C; Manughian-Peter AO; Chang SC; Chang G; Gago FE; Salomon MP; Marzese DM
    Ann Surg Oncol; 2019 Oct; 26(10):3185-3193. PubMed ID: 31342395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy.
    Zhang YS; Yang C; Han L; Liu L; Liu YJ
    Oncol Res Treat; 2022; 45(3):94-101. PubMed ID: 34775385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    J Cell Physiol; 2020 Sep; 235(9):6230-6245. PubMed ID: 32017076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
    Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
    Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Zheng T; Pang Z; Zhao Z
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
    Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
    Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    Wang RX; Chen S; Huang L; Shao ZM
    BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
    Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
    Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.